In the news release, UK NICE Issues Guidance Recommending Routine NHS Funding for Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion System, issued 27-Aug-2026 by Bridge to Life, Ltd. over PR Newswire, we are advised by the company that changes have been made. The complete, corrected release follows, with additional details at the end:
UK NICE Issues Guidance Recommending Routine NHS Funding for Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion SystemDULUTH, Ga, and LONDON, Aug. 27, 2026 /PRNewswire/ -- Bridge to Life™ Ltd., a global leader in organ preservation solutions and perfusion technologies, today highlighted the recent release of new HealthTech guidance by the United Kingdom's National Institute for Health and Care Excellence (NICE), recommending routine National Health Service (NHS) funding for ex-situ machine perfusion devices, including Bridge to Life's VitaSmart™ Hypothermic Oxygenated Perfusion (HOPE) System, to preserve deceased donor livers for transplantation.
Following a rigorous evaluation, NICE determined that advanced perfusion systems deliver clear clinical benefits over traditional static cold storage both clinically and financially, further noting that hypothermic oxygenated perfusion was associated with improved graft survival and fewer biliary complications. Additional details can be found in NICE's full guidance: Ex-situ machine perfusion devices to preserve deceased donor livers for transplantation (Reference number: HTG780. Published: August 20, 2026).
